COVID-19 Scan for Dec 04, 2020

Severe COVID in healthy younger adults
;
COVID-19 inflammatory syndrome in kids

CDC: 1 in 5 hospitalized younger adults with COVID-19 need ICU care

While younger adults with no underlying health conditions have been considered safer from COVID-19's severe outcomes, of those who were hospitalized, 22% were admitted to intensive care units (ICUs), 10% needed mechanical ventilation, and 0.6% (3 patients) died, reports a study published yesterday in Clinical Infectious Diseases.

The researchers, led by scientists with the Centers for Disease Control and Prevention's (CDC's) COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) team, used data from the network to look at patients to look at patients hospitalized with COVID-19 from March through August. During this period, 31.8% of the 44,865 patients in the COVID-NET system were adults under 50, of which 513 (3.9%, the study's cohort) had sufficient data to indicate they had no underlying diseases.

The study's patients most commonly experienced cough (61.7%), fever or chills (64.7%), and shortness of breath (63.4%) at the time of admission. According to their discharge records, though, health providers eventually diagnosed pneumonia in 51.1%, acute respiratory failure in 37.4%, and sepsis in 16.6%. The median hospital stay was 4 days, or 5 days if the patient was admitted to the ICU.

While the study did not look at the reasons behind these hospitalizations, the researchers noted that Hispanics represented 42.1% of patients compared with 16% in the general population. Additionally, men made up 74% of cases. The researchers say the association between men's increased angiotensin-converting enzyme 2 levels and COVID-19 severity may contribute to the level of severe disease found in the study population.
Dec 3 Clin Infect Dis study

 

Report shows connection between COVID-19, child inflammatory syndrome

A French study in Eurosurveillance yesterday shows an association between infection with SARS-CoV-2, the virus that causes COVID-19, and multisystem inflammatory syndrome in children (MIS-C), which is similar to Kawasaki disease. Researchers found 25-fold higher odds of exposure to the virus among patients with MIS-C.

Surges in MIS-C illness reports led to a UK National Health Service alert on Apr 25, which was followed by several regional case studies. No case-control studies—matching patients with and without the disease—have been conducted to date, the authors of the new study say. MIS-C symptoms can include fever, rash, conjunctivitis, abdominal pain, shock, elevated inflammatory markers, and cardiac damage.

This retrospective case-control study included 23 children with MIS-C admitted to a Paris hospital (mean age 6.8 years; range, 0.3 to 16.6 years) and 102 control patients (mean age 5.8 years; range 0.05 to 16.0 years) who visited Paris metropolitan area pediatric clinics from Apr 14 to May 26. Nasal swab samples for all children were tested for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT-PCR), and immunoassay tests of blood serum were used to identify anti–SARS-CoV-2 antibodies.

"Overall, 17 of 23 (74%) cases and 11 of 102 (11%) controls tested positive for SARS-CoV-2 by RT-PCR and/or serology (matched OR [odds ratio]: 26.4; 95% confidence interval (CI): 6.0–116.9)," the study authors found. "The association remained significant when limiting the assessment to RT-PCR results and serological results separately (matched OR: 13.9; 95% CI: 2.8 –68.6 and 27.7; 95% CI, 6.3–122.7, respectively)."

The strong association highlights the need for greater surveillance of infected children. "Clinicians should keep a high level of suspicion for [MIS-C] illness during the COVID-19 pandemic," the authors wrote.
Dec 3 Euro Surveill study

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Unorthodox Philanthropy logo and text 'Leading Underwriter'3M logoGilead 
Grant support for ASP provided by



bioMérieux

  Become an underwriter»